Antidiabetic Drugs Can Reduce the Harmful Impact of Chronic Smoking on Post-Traumatic Brain Injuries
International Journal of Molecular Sciences · 2023
DOI: 10.3390/ijms24076219 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Farzane Sivandzade und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biological Sciences, Oakland University, Rochester, MI 48309, USA. Hauptthemen laut MEDLINE: Metformin, Brain Injuries, Brain Injuries, Traumatic. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 107 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NINDS NIH HHS, NIDA NIH HHS, NHLBI NIH HHS.
Abstract (Originalsprache)
Traumatic Brain Injury (TBI) is a primary cause of cerebrovascular and neurological disorders worldwide. The current scientific researchers believe that premorbid conditions such as tobacco smoking (TS) can exacerbate post-TBI brain injury and negatively affect recovery. This is related to vascular endothelial dysfunction resulting from the exposure to TS-released reactive oxygen species (ROS), nicotine, and oxidative stress (OS) stimuli impacting the blood–brain barrier (BBB) endothelium. Interestingly, these pathogenic modulators of BBB impairment are similar to those associated with hyperglycemia. Antidiabetic drugs such as metformin (MF) and rosiglitazone (RSG) were shown to prevent/reduce BBB damage promoted by chronic TS exposure. Thus, using in vivo approaches, we evaluated the effectiveness of post-TBI treatment with MF or RSG to reduce the TS-enhancement of BBB damage and brain injury after TBI. For this purpose, we employed an in vivo weight-drop TBI model using male C57BL/6J mice chronically exposed to TS with and without post-traumatic treatment with MF or RSG. Our results revealed that these antidiabetic drugs counteracted TS-promoted downregulation of nuclear factor erythroid 2-related factor 2 (NRF2) expression and concomitantly dampened TS-enhanced OS, inflammation, and loss of BBB integrity following TBI. In conclusion, our findings suggest that MF and RSG could reduce the harmful impact of chronic smoking on post-traumatic brain injuries.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biological Sciences, Oakland University, Rochester, MI 48309, USA.
- Department of Foundation Medical Studies, Oakland University William Beaumont School of Medicine, Rochester, MI 48309, USA.
- Department of Pharmacology and Toxicology, College of Pharmacy, King Saud University, Riyadh 11362, Saudi Arabia.
- Department of Molecular and Cellular Physiology, Louisiana State University Health Shreveport, Shreveport, LA 71103, USA.
ORCID-Profile: Farzane Sivandzade, Faleh Alqahtani, Hemangini Dhaibar, Luca Cucullo
Förderung
- NINDS NIH HHS
- NIDA NIH HHS
- NHLBI NIH HHS
- NIGMS NIH HHS
- National Institutes of Health/National Institute
- National Institute of Neurological Disorders
Zitieren
APA
Sivandzade, F., Alqahtani, F., Dhaibar, H., Cruz-Topete, D., & Cucullo, L. (2023). Antidiabetic Drugs Can Reduce the Harmful Impact of Chronic Smoking on Post-Traumatic Brain Injuries. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms24076219
Vancouver
Sivandzade F, Alqahtani F, Dhaibar H, Cruz-Topete D, Cucullo L. Antidiabetic Drugs Can Reduce the Harmful Impact of Chronic Smoking on Post-Traumatic Brain Injuries. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms24076219
BibTeX
@article{Sivandzade2023,
author = {Sivandzade, Farzane and Alqahtani, Faleh and Dhaibar, Hemangini and Cruz-Topete, Diana and Cucullo, Luca},
title = {Antidiabetic Drugs Can Reduce the Harmful Impact of Chronic Smoking on Post-Traumatic Brain Injuries},
journal = {International Journal of Molecular Sciences},
year = {2023},
doi = {10.3390/ijms24076219}
}
EUVIMED